Amgen's PCSK9 inhibitor prevails in third Phase III study
This article was originally published in Scrip
Executive Summary
Amgen reported positive top-line results from the third of 13 Phase III clinical trials for the company's cholesterol-lowering biologic evolocumab (AMG 145), which met the GAUSS-2 study's co-primary endpoints in the treatment of 307 statin-intolerant patients.